[Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

SVF Endurance (Cayman) Ltd and related SoftBank entities reported insider sales of Vir Biotechnology, Inc. (VIR) common stock under a Rule 10b5-1 plan. The filings show a sale of 72,133 shares on 10/07/2025 at a weighted average price of $5.6029 and a sale of 466,242 shares on 10/08/2025 at a weighted average price of $6.0479. After the reported transactions, the beneficial ownership attributable indirectly to the reporting group declined from 16,087,611 shares to 15,621,369 shares. The filings state the sales were effected pursuant to a 10b5-1 trading plan entered on September 3, 2025, and identify SVF Endurance as a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited acting as AIFM.

Positive

• Sales executed under a documented Rule 10b5-1 plan, which provides pre-arranged compliance protection
• Filing discloses weighted-average prices and share ranges, and offers to provide breakdowns on request

Negative

• Beneficial ownership declined by 466,242 shares to 15,621,369 shares following the reported sales
• Large institutional holder reduced stake, which may be interpreted as downward pressure on insider ownership

Insights

Institutional Investor Relations Analyst

Insider sales under a 10b5-1 plan reduced SoftBank's indirect stake by about 2.9.

The reported transactions show scheduled sales executed under a 10b5-1 plan, which is a pre‑arranged program that allows large holders to sell shares without contemporaneous trading intent. The group sold 72,133 shares at a weighted average of $5.6029 and 466,242 shares at a weighted average of $6.0479, leaving 15,621,369 shares indirectly owned.

Dependence on the 10b5-1 plan reduces the immediacy of signal from the sales, but the transactions do lower the block holding. Investors may watch outstanding share counts and block ownership disclosures over the next quarters for further scheduled sales or changes in beneficial ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2025		S(1)		72,133	D	$5.6029(2)	16,087,611	I	See footnote(3)
Common Stock	10/08/2025		S(1)		466,242	D	$6.0479(4)	15,621,369	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SOFTBANK VISION FUND (AIV M1) L.P.

(Last) (First) (Middle)

1521 CONCORD PIKE

(Street)

WILMINGTON, DE 19803

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SB INVESTMENT ADVISERS (UK) LTD

(Last) (First) (Middle)

69 GROSVENOR STREET

(Street)

LONDON, X0 W1K 3JP

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.52 to $5.675. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6101 to $6.325. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director	10/09/2025
	SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel	10/09/2025
	SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did SoftBank entities sell in the VIR Form 4?

They reported selling 72,133 shares on 10/07/2025 at a weighted average price of $5.6029 and 466,242 shares on 10/08/2025 at a weighted average price of $6.0479.

Were the VIR sales part of a trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2025.

How did the reported transactions change SoftBank's stake in VIR?

Beneficial ownership attributed to the reporting group decreased from 16,087,611 shares to 15,621,369 shares after the reported transactions.

Which SoftBank entities filed the Form 4 for VIR?

The filers include SVF Endurance (Cayman) Limited, SoftBank Vision Fund (AIV M1) L.P., and SB Investment Advisers (UK) Limited acting in managerial capacity.

Are the reported sale prices exact per-share prices?

The Form 4 lists weighted-average prices ($5.6029 and $6.0479) and discloses the ranges of transaction prices within footnotes.